• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Amedisys Inc

    1/6/23 12:47:16 PM ET
    $AMED
    Medical/Nursing Services
    Health Care
    Get the next $AMED alert in real time by email
    SC 13G 1 AMEDISYS_INC.htm FILING AMEDISYS, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     
    AMEDISYS, INC. 

    (Name of Issuer)
     
    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     
    023436108

    (CUSIP Number)
     
    December 30, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  023436108            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      1,663,943
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      1,760,024
         
    8   SHARED DISPOSITIVE POWER
       
      0
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      1,763,327
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.4 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    AMEDISYS, INC.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    3854 American Way, Suite A,
    Baton Rouge, LA 70816


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Common Stock, par value $0.001 per share


     
    (e)
    CUSIP Number
     
     
    023436108


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 1,763,327


     
    (b)
    Percent of class: 5.4 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 1,663,943


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 1,760,024


     
    (iv)
    Shared power to dispose or to direct the disposition of: 0


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Trust Company of Delaware
    J.P. Morgan Securities LLC
    JPMorgan Chase Bank, National Association
    J.P. Morgan Investment Management Inc.
    55I, LLC
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: January 06, 2023
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $AMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMED

    DatePrice TargetRatingAnalyst
    7/29/2024$101.00Buy → Hold
    Deutsche Bank
    7/1/2024Outperform → Mkt Perform
    William Blair
    6/7/2023$97.00Buy → Hold
    Truist
    4/21/2023$87.00Neutral
    Cantor Fitzgerald
    3/13/2023$93.00Equal Weight
    Barclays
    10/27/2022Outperform → Mkt Perform
    Raymond James
    8/2/2022$145.00 → $95.00Neutral → Sell
    UBS
    6/29/2022$128.00Hold
    Stifel
    More analyst ratings

    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 171 shares, decreasing direct ownership by 2% to 7,943 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      6/3/25 8:18:53 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Guidroz Allyson sold $35,904 worth of shares (374 units at $96.00), decreasing direct ownership by 4% to 8,114 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/9/25 4:05:58 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 273 shares, decreasing direct ownership by 3% to 8,488 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/6/25 8:24:14 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Financials

    Live finance-specific insights

    See more
    • AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

      BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

      5/3/23 4:31:00 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

      All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

      5/3/23 4:30:00 PM ET
      $AMED
      $OPCH
      Medical/Nursing Services
      Health Care
    • Amedisys Announces First Quarter 2023 Earnings Release and Conference Call Date

      BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

      4/20/23 8:00:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amedisys Reports First Quarter 2025 Financial Results

      BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 milli

      4/23/25 4:45:43 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

      BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, 2024 and 2023 Net service revenue increased $27.3 million to $598.1 million compared to $570.8 million in 2023.Net loss attributable to Amedisys, Inc. of $20.4 million, which is inclusive of merger-related expenses totaling $17.4 million ($15.9 million, net of tax) and a non-cash goodwill and other intangibles impairment charge totaling $48.4 million ($38.4 million, net of noncontrolling interest and tax) compared to net income attributable to Amedisys, Inc. of $19.3 milli

      2/26/25 4:30:12 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Honors 47 Employees With Annual Spirit of Excellence Award

      BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are privileged to have exceptional clinicians who consistently exceed expectations, and it is a profound honor to recognize their incredible commitment." Each year, the company honors Home

      2/3/25 6:30:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Amedisys Reports Second Quarter 2024 Financial Results

      BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa

      7/24/24 4:30:52 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports First Quarter 2024 Financial Results

      BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o

      4/24/24 4:45:46 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

      BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s

      2/21/24 4:30:11 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    SEC Filings

    See more
    • SEC Form 8-K filed by Amedisys Inc

      8-K - AMEDISYS INC (0000896262) (Filer)

      5/1/25 5:00:16 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form 10-K/A filed by Amedisys Inc

      10-K/A - AMEDISYS INC (0000896262) (Filer)

      4/29/25 4:12:39 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Amedisys Inc

      10-Q - AMEDISYS INC (0000896262) (Filer)

      4/24/25 8:02:23 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/13/24 4:58:48 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/12/24 5:24:28 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/8/24 10:18:47 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amedisys downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00

      7/29/24 7:29:37 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by William Blair

      William Blair downgraded Amedisys from Outperform to Mkt Perform

      7/1/24 7:29:43 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by Truist with a new price target

      Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00

      6/7/23 9:03:46 AM ET
      $AMED
      Medical/Nursing Services
      Health Care